DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ...

GuruFocus News

Thu, May 15, 2025, 12:09 AM 4 min read

• Cash and Investments: $37.3 cardinal arsenic of March 31, 2025.

• Current Liabilities: $4.7 cardinal arsenic of March 31, 2025.

• Working Capital: $32.8 cardinal arsenic of March 31, 2025.

• Net Cash Used successful Operating Activities: $7.1 cardinal for Q1 2025.

• Research and Development Expenses: $5.7 cardinal for the 3 months ended March 31, 2025.

• General and Administrative Expenses: $2.5 cardinal for the 3 months ended March 31, 2025.

• Net Other Income: $443,000 for the 3 months ended March 31, 2025.

• Warning! GuruFocus has detected 1 Warning Sign with DMAC.

Release Date: May 14, 2025

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

• DiaMedica Therapeutics Inc (NASDAQ:DMAC) is making important advancement successful its objective improvement programs, peculiarly successful the preeclampsia and changeable areas.

• The institution is adjacent to identifying a people dose for its signifier 2 preeclampsia trial, with preliminary top-line results expected betwixt June and July.

• Enrollment successful the changeable programme is progressing steadily, with subordinate enrollment reaching betwixt the 20th and 25th percentile mark.

• The institution has engaged an experienced changeable neurologist to enactment tract engagement and support enrollment momentum successful the Remedy II trial.

• DiaMedica Therapeutics Inc (NASDAQ:DMAC) has a beardown fiscal presumption with a full combined currency and investments of $37.3 cardinal arsenic of March 31, 2025, providing a runway into Q3 of 2026.

• The company's nett currency utilized successful operating activities accrued to $7.1 cardinal for the archetypal 4th of 2025, up from $6.7 cardinal successful the aforesaid play of 2024.

• Research and improvement expenses roseate importantly to $5.7 cardinal for the 3 months ended March 31, 2025, compared to $3.7 cardinal for the aforesaid play successful 2024.

• General and administrative expenses accrued to $2.5 cardinal for the 3 months ended March 31, 2025, from $2.1 cardinal successful the aforesaid play of 2024.

• The institution anticipates that R&D expenses volition moderately summation successful aboriginal periods owed to the continuation of the Remedy II proceedings and enlargement of the DM 199 objective improvement program.

• Interest income decreased, resulting successful a nett different income of $443,000 for the 3 months ended March 31, 2025, compared to $597,000 for the aforesaid play successful 2024.

Q: Can you clarify the laboratory trial results that are affecting the readout timing betwixt June and July? Is it chiefly the trial for DM 199 crossing the placental barrier? A: Yes, the main point is the placental transfer. We person an assay being finalized to observe little limits, and it's a substance of clip for them to tally it. We provided a scope for erstwhile we expect the results. - Rick Pauls, President & CEO

Q: What are the triggers for parts 2 and 3 of the preeclampsia study? A: For fetal maturation restrictions, if we spot dilation of the intrauterine arteries, our investigators are prepared to determination up with that cohort. More details connected portion 2 volition beryllium shared erstwhile we merchandise the results. - Rick Pauls, President & CEO

Q: Can you sermon the anticipated read-through oregon de-risking betwixt the archetypal preeclampsia information and however it could construe to AIS improvement and the Remedy II trial? A: These are unsocial indications, but a affirmative effect successful preeclampsia confirms the protein's activity. The macromolecule is utilized successful Asia for changeable and preeclampsia, which supports our rationale for some indications. - Rick Pauls, President & CEO

Q: Can you supply details connected changeable programme enrollment, peculiarly high-volume centers? A: We spot momentum with high-enrolling sites achieving 1-2 patients per tract per month. We're focusing connected these sites to physique momentum and are presently supra our plan. - Rick Pauls, President & CEO

Q: Have you expanded the fig of centers for the changeable program, and is determination planetary enrollment? A: We are successful the mid-30s for sites, focusing connected high-enrolling ones. We person sites successful Georgia (country) performing well. - Rick Pauls, President & CEO

Q: Will parts 2 and 3 of the preeclampsia survey beryllium based successful South Africa, oregon volition determination beryllium a US component? A: Parts 2 and 3 are nether the aforesaid protocol, truthful nary request for caller regulatory clearance. We program to grow to the US and globally successful the future. - Rick Pauls, President & CEO

Q: Are you seeing an summation successful enrollment rates for the changeable program? A: Yes, since the past net call, we've seen an encouraging uptick successful enrollment rates. - Rick Pauls, President & CEO

Q: What is the fiscal outlook for DiaMedica, and however agelong is the currency runway? A: As of March 31, 2025, we person $37.3 cardinal successful currency and investments, providing a runway into Q3 of 2026. - Scott Kellen, CFO

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

This nonfiction archetypal appeared connected GuruFocus.